← Eichor
Condition: Chronic Leukemia Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Chronic Leukemia

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Long-term Extension Study of PCI-32765 (Ibrutinib)
Phase 3 · 175 location(s) · Janssen Research & Development, LLC · NCT01804686Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Pat
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT07128381Zanubrutinib and Venetoclax in CLL (ZANU-VEN)
Phase 2 · 4 location(s) · Dana-Farber Cancer Institute · NCT05168930AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Phase 1 · 13 location(s) · Carna Biosciences, Inc. · NCT05602363Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia
NA · 1 location(s) · Peking University People's Hospital · NCT07588594TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
Phase 1 · 2 location(s) · Shenzhen TargetRx Co., Ltd. · NCT06088888Investigating the Role of Energy Balance Modification on Health Responses in Chronic Lymphocytic Leukaemia
NA · 1 location(s) · University of Surrey · NCT06379282MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing
NA · 1 location(s) · Medical College of Wisconsin · NCT05794880Methods of T Cell Depletion Trial (MoTD)
Phase 2 · 17 location(s) · University of Birmingham · NCT04888741CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Phase 1 · 4 location(s) · Catapult Therapeutics · NCT04704323REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)
Phase 2 · 18 location(s) · Stichting Hemato-Oncologie voor Volwassenen Nederland · NCT04523428A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib
Phase 3 · 91 location(s) · BeOne Medicines · NCT07277231Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
Phase 2/Phase 3 · 1 location(s) · M.D. Anderson Cancer Center · NCT04708054Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT03128879Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Phase 2 · 24 location(s) · Novartis Pharmaceuticals · NCT07354074MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel
Phase N/A · 2 location(s) · MPN Research Foundation · NCT07362225Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Phase 2 · 1 location(s) · National Heart, Lung, and Blood Institute (NHLBI) · NCT03986034Use of Preoperative Postbiotic Supplementation in Colorectal Cancer Surgery
NA · 1 location(s) · AC Camargo Cancer Center · NCT07268846Cardiovascular Prevention Strategies in Elderly Patients With Cancer (CARTIER Clinical Trial)
NA · 14 location(s) · Fundación Instituto de Estudios de Ciencias de la Salud de C · NCT03711110A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab a
Phase 1 · 31 location(s) · Hoffmann-La Roche · NCT05091424Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Phase 2 · 3 location(s) · Massachusetts General Hospital · NCT04560322Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
Phase N/A · 14 location(s) · University Hospital, Clermont-Ferrand · NCT05246345A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and
Phase 2 · 2 location(s) · M.D. Anderson Cancer Center · NCT06566742A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 4 · 50 location(s) · Eli Lilly and Company · NCT07218341Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Mod
Phase N/A · 8 location(s) · Bristol-Myers Squibb · NCT06357754Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Le
Phase 2 · 8 location(s) · National Cancer Institute (NCI) · NCT07061951Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-
Phase 1 · 8 location(s) · Newave Pharmaceutical Inc · NCT04771572Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Underg
Phase 1 · 1 location(s) · M.D. Anderson Cancer Center · NCT03630991Study on the Diagnosis and Management of CLL in Italy by GIMEMA
Phase N/A · 24 location(s) · Gruppo Italiano Malattie EMatologiche dell'Adulto · NCT04867915A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia
Phase 2 · 1 location(s) · Korean Society of Hematology · NCT06368414
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.